Cellular Repair & Recovery
Thymosin Alpha-1
Thymalfasin
Thymosin Alpha-1 (Thymalfasin)
Research context
Thymosin alpha-1 is an acetylated 28-residue peptide first characterised from thymosin fraction 5. Research examines Toll-like receptor signalling, dendritic cell maturation markers, and T-cell subset distribution in cell culture and animal models.
Common assays: TLR9/TLR2 reporter assays · Dendritic cell maturation markers · T-cell subset flow cytometry
Specification
| Designation | Thymalfasin |
|---|---|
| Full name | Thymosin Alpha-1 (Thymalfasin) |
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn |
| CAS number | 62304-98-7 |
| Molecular formula | C129H215N33O55 |
| Molecular weight | 3108.30 g/mol |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Sterile water, bacteriostatic water |
| Storage | Lyophilised: −20 °C, desiccated. Reconstituted: 2–8 °C. |
| Regulatory status | Not an approved drug. Withdrawn from FDA 503A Category 2 in 2024; the advisory committee voted against adding it to the 503A bulks list in late 2024. 2026 status by compound → |
| Current lot | TA10VAS0126 → |
Thymosin Alpha-1 COA: certificates of analysis by lot
2 lots of Thymosin Alpha-1 have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| TA10VAS0126 | 10 mg Vial | >99.5% | 2026-02-20 |
| TA20N1125 | 20 mg Spray | >99.0% | 2025-11-24 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Goldstein AL, Goldstein AL.From lab to bedside: emerging clinical applications of thymosin alpha 1Expert Opinion on Biological Therapy · 2009 Find on PubMed ↗
- Romani L, Bistoni F, Gaziano R, et al.Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signalingBlood · 2004 Find on PubMed ↗
Common questions
Why is Thymosin Alpha-1 N-terminally acetylated?
The native peptide is acetylated in vivo, and the acetyl group is retained in synthetic preparations to match the characterised form. Acetylation state is confirmed by tandem MS on each lot.
How is a 28-residue peptide verified for purity?
HPLC-UV for purity and LC-MS for mass confirmation. For peptides of this length, peptide content by nitrogen analysis is also reported, since net weight includes counterions and residual water.
Where can I see the Thymosin Alpha-1 certificate of analysis?
Every published Thymosin Alpha-1 lot has its own certificate page on this site, listed under "Thymosin Alpha-1 COA" above. There are 2 published lots; the most recent, lot TA10VAS0126, was reported on 2026-02-20 at >99.5% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
Thymosin Alpha-1 / KPV
Peptide blend
A prepared blend combining a thymic peptide with the α-MSH C-terminal tripeptide.
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
Wolverine
BPC-157 / TB-500
A prepared blend of the two most extensively studied compounds in the repair signalling literature.